EE+ POEM Archive
PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES)
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "PSK9 Inhibitor Alirocumab Reduces Nonfatal MI in Patients After Acute Coronary Syndrome, but at High Cost (ODYSSEY OUTCOMES)." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314667/all/PSK9_inhibitor_alirocumab_reduces_nonfatal_MI_in_patients_after_acute_coronary_syndrome_but_at_high_cost__ODYSSEY_OUTCOMES_.
PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES). In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314667/all/PSK9_inhibitor_alirocumab_reduces_nonfatal_MI_in_patients_after_acute_coronary_syndrome_but_at_high_cost__ODYSSEY_OUTCOMES_. Accessed April 19, 2024.
PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES). (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314667/all/PSK9_inhibitor_alirocumab_reduces_nonfatal_MI_in_patients_after_acute_coronary_syndrome_but_at_high_cost__ODYSSEY_OUTCOMES_
PSK9 Inhibitor Alirocumab Reduces Nonfatal MI in Patients After Acute Coronary Syndrome, but at High Cost (ODYSSEY OUTCOMES) [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2024 April 19]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314667/all/PSK9_inhibitor_alirocumab_reduces_nonfatal_MI_in_patients_after_acute_coronary_syndrome_but_at_high_cost__ODYSSEY_OUTCOMES_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - PSK9 inhibitor alirocumab reduces nonfatal MI in patients after acute coronary syndrome, but at high cost (ODYSSEY OUTCOMES)
ID - 1314667
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314667/all/PSK9_inhibitor_alirocumab_reduces_nonfatal_MI_in_patients_after_acute_coronary_syndrome_but_at_high_cost__ODYSSEY_OUTCOMES_
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -
